| Topic | HORIZON-MISS-2027-02-CANCER-01 |
|---|---|
| Status | Forthcoming |
| Call | HORIZON-MISS-2027-02 — Supporting the implementation of the Cancer Mission |
| Type of action | Research and Innovation Actions |
| Opening | 10 February 2027 |
| Deadline | 16 September 2027 |
| Budget | EUR 7 million to EUR 8 million per project · 4 projects expected · EUR 32.32 million in total |
| Part B page limit | 40 pages (standard application form; check your call) |
| Template | Work Programme 2026–2027 application form |
Expected outcomes
Projects should contribute to all of the expected outcomes. The topic says: “Proposals under this topic should aim to deliver results that are directed and tailored towards and contribute to all of the following expected outcomes:”
- EO1 Researchers and health professionals gain a deeper understanding of the functional effects of tumour heterogeneity during cancer initiation and progression, supporting the identification of more precise and novel therapeutic targets.
- EO2 Researchers, health professionals and innovators benefit from improved knowledge and tools to support the discovery and development of next generation genomically-informed cancer treatments.
- EO3 Researchers, innovators, and professionals across disciplines and sectors contribute to the UNCAN.eu research data platform by ensuring data interoperability, and enabling sustainable access to newly developed digital tools and models for the analysis and management of multimodal clinical data.
What evaluators will look for in this topic
Expected outcomes
- Projects should contribute to all of the expected outcomes.
- For each outcome (EO1 to EO3), name who will use or adopt your results (a specific group, not “industry” or “society”), how they get them, and the indicator that shows the change, with baseline, target and date.
- Use the topic's own words for each outcome, so the evaluator can tick it off.
What the scope asks for
Evaluators check the proposal against these sentences of the scope. Answer each one visibly, in the call's own words.
- “Applicants are encouraged to leverage technological advances in functional genomics and structural biology including but not limited to rapid gene sequencing, single-cell studies, spatial gene mapping, spatial transcriptomics, epigenetic profiling, liquid biopsies and functional precision oncology pipelines.”
- “The use of causal inference, computational modelling and/or artificial intelligence tools is encouraged for the collection, visualisation, analysis and management of large, complex, and heterogeneous data sets.”
- “Applicants should address all of the following activities:.”
- “These digital assets should be made available through the UNCAN.eu research platform.”
- “All datasets produced should be described with metadata records in the EU dataset catalogue of the European Health Data Space.”
- “The involvement of existing ESFRI research infrastructures offering life science resources including biobanking options should be appropriately reflected in the proposal workplan.”
- “Advantage should be taken to the extent possible of data and experience gained under current large-scale initiatives such as: the European 1M+ Genomes and the European Cancer Imaging initiative and others as appropriate.”
- “Successful proposals are expected to establish appropriate collaborations with the project UNCAN-CONNECT that is implementing the UNCAN.eu research platform.”
- “Successful proposals will be asked to join the 'Understanding' project cluster of the Cancer Mission and should include a budget for networking, attendance at meetings, and joint activities.”
- “Applicants envisaging to include clinical studies should provide details in the dedicated annex using the template provided in the submission system.”
- “Proposals should include an appropriate mix of stakeholders from various disciplines and sectors, including but not limited to medical doctors, health-IT experts, researchers, AI-experts, solution providers, academia and research institutes, EU research infrastructures and SMEs.”
Conditions that shape the proposal
- Part B, sections 1–3: 40 pages (standard application form). Text beyond the limit is not read; tables and figures count.
- Other Eligibility Conditions: “Subject to restrictions for the protection of European communication networks.”
- Evaluation and award: Submission and evaluation processes: “The thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 4 (Implementation). The cumulative threshold is 12.”
Impact pathway and traps
- Users or citizens are part of the scope. Show how they take part in the design and testing, not only that they are informed.
- Open science or data practices are named. Make the data management plan concrete: which data, which repository, when.
- Keep outputs, outcomes and impacts apart: what you deliver, what changes when others use it, and the long-term effect.
- Link your outcomes to the destination's expected impacts in the Work Programme. Destination impacts are long-term effects, not project deliverables.
- Name the barriers outside the project (regulation, markets, user behaviour) that could block uptake, and what you will do if they do.
- Section 2.3 (the summary canvas) is optional on this call; the old split into scientific, economic and societal impact is no longer required.
The scope, as published
The proposed topic will contribute to the EU Cancer Mission objective of improving the understanding of cancer initiation and progression. Of particular interest for this topic are paediatric and adolescent cancers, cancers with limited treatment options, refractory cancers, rare cancers or cancer types with low five-year survival rates. Proposals may include the design of exploratory mechanistic studies using longitudinal patient bio-samples, clinical proof-of-concept studies and/or observational and translational studies involving newly collected or existing data, as appropriate. Applicants are encouraged to leverage technological advances in functional genomics and structural biology including but not limited to rapid gene sequencing, single-cell studies, spatial gene mapping, spatial transcriptomics, epigenetic profiling, liquid biopsies and functional precision oncology pipelines. The use of causal inference, computational modelling and/or artificial intelligence tools is encouraged for the collection, visualisation, analysis and management of large, complex, and heterogeneous data sets. Collaboration among different scientific disciplines, including healthcare professionals, is envisaged. Applicants should address all of the following activities: To identify and validate new targets for innovative therapeutic approaches, by developing experimental models and technologies to access the functional effects of tumour temporal heterogeneity on disease initiation, progression and relapse. To investigate the mechanisms underlying the interply between the tumor’s dynamic multi-omics characteristics, its microenvironment and patient specific factors during disease initiation and progression. This includes elucidating the mechanisms of adaptive resistance to therapies, utilizing clinical data where appropriate. To apply state-of-the-art approaches, tools and models to integrate and analyse FAIR (Findable, Accessible, Interoperable, Reusable) multimodal longitudinal patient data. These digital assets should be made available through the UNCAN.eu research platform. All datasets produced should be described with metadata records in the EU dataset catalogue of the European Health Data Space. The involvement of existing ESFRI research infrastructures offering life science resources including biobanking options should be appropriately reflected in the proposal workplan. Advantage should be taken to the extent possible of data and experience gained under current large-scale initiatives such as: the European 1M+ Genomes and the European Cancer Imaging initiative and others as appropriate. Successful proposals are expected to establish appropriate collaborations with the project UNCAN-CONNECT that is implementing the UNCAN.eu research platform. Successful proposals will be asked to join the 'Understanding' project cluster of the Cancer Mission and should include a budget for networking, attendance at meetings, and joint activities. The Commission will facilitate coordination of these activities. Applicants envisaging to include clinical studies should provide details in the dedicated annex using the template provided in the submission system. Age at first diagnosis 0-19 years The use of transcriptomics, proteomics, epigenomics, and metabolomics to understand gene function in a systems biology context Proposals should include an appropriate mix of stakeholders from various disciplines and sectors, including but not limited to medical doctors, health-IT experts, researchers, AI-experts, solution providers, academia and research institutes, EU research infrastructures and SMEs Any relevant preclinical or clinical model including but not limited to in silico, in vitro, in vivo or ex vivo models such as: genetic background, immune status, age, sex, and comorbidities applicants may build over existing clinically annotated patient cohorts and exploit current EU biobanks for sample access https://lifescience-ri.eu/home.html European '1+ Million Genomes' Initiative | Shaping Europe’s digital future European Cancer Imaging Initiative | Shaping Europe’s digital future https://cordis.europa.eu/project/id/101215206 In order to address the objectives of the Cancer Mission, participants will collaborate in project clusters to leverage EU-funding, increase networking across sectors and disciplines, and establish a portfolio of Cancer Mission R&I and policy actions Examples of those activities are organising joint workshops, establishing best practices, joint communication or citizen engagement activities with projects funded under other clusters and pillars of Horizon Europe, or other EU programmes, as appropriate. Proposals are not required to include details of these activities, as they will be defined during the grant agreement preparation and during the life of the project
Other topics in HORIZON-MISS-2027-02
- HORIZON-MISS-2027-02-CANCER-02 — Clinical research by Comprehensive Cancer Infrastructures for the benefit of…
- HORIZON-MISS-2027-02-CANCER-03 — Phase 1 including first-in-human clinical trials to test biomarker-guided…
- HORIZON-MISS-2027-02-CANCER-04 — Improving equitable health outcomes and added value for and with cancer…
- HORIZON-MISS-2027-02-CANCER-05 — Pre-commercial procurement of affordable solutions for healthcare systems in…
- HORIZON-MISS-2027-02-CANCER-06 — Support a Young Cancer Survivor Quality of Life (QoL) research programme by…
Source and attribution
Topic text from the official topic page on the EU Funding & Tenders Portal, retrieved 19 October 2026. © European Union, reused under Commission Decision 2011/833/EU (CC BY 4.0). Changes: the expected outcomes and impacts are split into numbered statements, long passages are shortened, and the evaluator checklist is GrantWise's own commentary. Your call and the Work Programme always win; check them before you submit. GrantWise is independent and not affiliated with, endorsed by, or acting on behalf of the European Commission.